Previous Close | 3.8100 |
Open | 3.8000 |
Bid | 2.7600 x 200 |
Ask | 4.5000 x 200 |
Day's Range | 3.5000 - 3.8600 |
52 Week Range | 1.0300 - 5.0700 |
Volume | |
Avg. Volume | 165,200 |
Market Cap | 112.405M |
Beta (5Y Monthly) | 2.44 |
PE Ratio (TTM) | N/A |
EPS (TTM) | N/A |
Earnings Date | N/A |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
Neuronetics (STIM) announces the FDA's approval of NeuroStar Advanced Therapy, which is likely to aid in the treatment of depression in adolescents by acting as a supplement.
The collaboration between Neuronetics (STIM) and TCN holds particular significance in the realm of treatment-resistant depression.
Strong Utilization Trends and Operational Highlights Drive Growth